Alpha Teknova (TKNO) Net Income towards Common Stockholders (2020 - 2026)
Alpha Teknova (TKNO) posted quarterly Net Income towards Common Stockholders of -$4.6 million for Q1 2026, up 1.94% year-over-year from -$4.5 million in Q1 2025, and up 3.64% quarter-over-quarter from -$4.7 million in Q4 2025.
Alpha Teknova (TKNO) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Alpha Teknova (TKNO) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$4.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 1.94% year-over-year to -$4.6 million; the TTM figure through Mar 2026 stood at -$17.2 million (up 26.33% YoY), while the FY2025 annual figure was -$17.2 million, up 35.66% from the prior year.
- Net Income towards Common Stockholders climbed to -$4.6 million in Q1 2026 per TKNO's latest filing, from -$4.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$3.6 million in Q2 2025 and bottomed at -$22.4 million in Q3 2022.
- Historically, Net Income towards Common Stockholders has averaged -$7.9 million across 5 years, with a median of -$6.2 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 732.98% — and 2023, when it soared 54.77%.
- Alpha Teknova's Net Income towards Common Stockholders stood at -$15.2 million in 2022, then gained by 27.88% to -$11.0 million in 2023, then jumped by 47.82% to -$5.7 million in 2024, then rose by 17.35% to -$4.7 million in 2025, then increased by 3.64% to -$4.6 million in 2026.
- Business Quant data shows TKNO's Net Income towards Common Stockholders at -$4.6 million in Q1 2026, -$4.7 million in Q4 2025, and -$4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alpha Teknova | 374.37 Mn | 356.94 Mn | 4.89 Mn | -3.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.17 Mn |
| Mar 31, 2026 | -4.56 Mn |
| Dec 31, 2025 | -4.73 Mn |
| Sep 30, 2025 | -4.31 Mn |
| Jun 30, 2025 | -3.57 Mn |
| Mar 31, 2025 | -4.65 Mn |
| Dec 31, 2024 | -5.72 Mn |
| Sep 30, 2024 | -7.57 Mn |
| Jun 30, 2024 | -5.36 Mn |
| Mar 31, 2024 | -8.10 Mn |
| Dec 31, 2023 | -10.96 Mn |
| Sep 30, 2023 | -10.15 Mn |
| Jun 30, 2023 | -7.15 Mn |
| Mar 31, 2023 | -8.82 Mn |
| Dec 31, 2022 | -15.20 Mn |
| Sep 30, 2022 | -22.45 Mn |
| Jun 30, 2022 | -6.20 Mn |
| Mar 31, 2022 | -5.46 Mn |
| Dec 31, 2021 | -6.48 Mn |
| Sep 30, 2021 | -3.24 Mn |